Clinical trials: PD-1 Inhibitor
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients…
- Conditions
- Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
- Trial name
- ACTION (NCT05352828)
- Testing
- Nivolumab, Autologous CD30.CAR-T, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Tessa Therapeutics
Malignant Melanoma Stage III
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
This is an international (Australia, Europe, and USA) open-label two-arm randomized phase 3 trial including 420 stage III (≤3 resectable in-transit metastases allowed) cutaneous or unknown primary melanoma patients.
- Trial name
- NADINA (NCT04949113)
- Testing
- Neoadjuvant ipilimumab + nivolumab, Adjuvant nivolumab
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 423 people
- Sponsor
- The Netherlands Cancer Institute
Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma
Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
The investigators hypothesize that combination anlotinib with toripalimab will improve progression-free survival relative to historical controls in patients with Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma.
- Trial name
- NCT03946943
- Testing
- Anlotinib, Toripalimab, Blood Draw
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Di Wu
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
This is a Phase I, open-label multi-site trial designed to evaluate the safety of administering rapidly-generated Tumor associated antigen specific T cells (TAA-T) with the Programmed Death1 (PD-1) inhibitor Nivolumab, in…
- Trial name
- NCT03843294
- Testing
- TAA-T cells, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Catherine Bollard
Colorectal Cancer
Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer
Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy.
- Trial name
- NCT05414461
- Testing
- Combinations
- Where
- China
- Volunteers
- 97 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed).
- Trial name
- NCT04546399
- Testing
- 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection
- Where
- 227 sites in United States, Australia and 2 more
- Volunteers
- 461 people
- Sponsor
- National Cancer Institute (NCI)
Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
Currently, treatment options for Epstein-Barr virus (EBV) infection are limited, with unsatisfactory efficacy and no established standard therapy.
- Conditions
- Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir, Chidamide
- Trial name
- NCT07133776
- Testing
- PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases.
- Volunteers
- 30 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Rectal Cancer, Colon Cancer
Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival
This trial is a single-center retrospective study. Eligible patients receiving PD-1 inhibitor treatment will enrolled.
- Trial name
- NCT06900686
- Testing
- PD1 Inhibitor
- Volunteers
- 458 people
- Sponsor
- Yanhong Deng
Hodgkin Lymphoma
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma
- Trial name
- NCT07641010
- Testing
- PD-1+JAK1i, PD-1
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Transitional Cell Tumor, Hepatoblastoma
Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy
This is a single arm, open-label trial studying the combination of PD-1/PD-L1 Inhibitor (e.g.pembrolizumab, Sintilimab,Duvarizumab，Camrelizumab )and lenvatinib given at the recommended dose in pediatric and young adolescent…
- Conditions
- Transitional Cell Tumor, Hepatoblastoma, Liver Cancer, Pediatric Solid Tumor
- Trial name
- sPLENTY-pc (NCT05322187)
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 15 people
- Sponsor
- RenJi Hospital
Non-Small Cell Lung Cancer, Neoadjuvant Therapy
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
This is an exploratory clinical study focusing on the neoadjuvant treatment of non-small cell lung cancer (NSCLC). The study primarily aims to compare the efficacy and safety of Ivonescimab, a novel PD-1/VEGF bispecific antibody…
- Conditions
- Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy
- Trial name
- NCT07359040
- Testing
- Ivonescimab, PD-1 Inhibitors
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantation
- Trial name
- NCT05772273
- Testing
- Azacitidine, Donor lymphocyte infusion, Camrelizumab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, B-cell, Lymphoma, B-Cell
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
This study combines the immune checkpoint inhibitor pembrolizumab with the BITE antibody blinatumomab for the treatment of relapsed/refractory pre-B cell ALL.
- Trial name
- NCT03605589
- Testing
- Blinatumomab, Pembrolizumab
- Where
- United States
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Uveal Melanoma
Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
- Trial name
- imMUno (NCT03964298)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Curie
Nasopharyngeal Cancer Recurrent
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
- Trial name
- TRANSPARENT (NCT06457503)
- Testing
- Toripalimab, Cisplatin, Gemcitabine
- Where
- 13 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Coherus Oncology, Inc.
Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies
Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation
The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.
- Trial name
- ImmunEO (NCT04609930)
- Testing
- Anti-PD-1 or anti-PD-L1
- Where
- France
- Volunteers
- 143 people
- Sponsor
- University Hospital, Montpellier
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Trial name
- NCT02879695
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Neoplasms
Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced…
- Trial name
- AIPAAIAEC (NCT05349045)
- Testing
- an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Hepatocellular Carcinoma
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma
This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Hepatocellular Carcinoma(HCC).This study aims to evaluate the safety and efficacy…
- Trial name
- HCC-009 (NCT04297202)
- Testing
- Apatinib Combined With SHR-1210 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University